Applied Therapeutics, Inc. (APLT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Applied Therapeutics, Inc. (APLT) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESSWIRE / December 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Applied Therapeutics, Inc. (APLT)
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Applied Therapeutics, Inc. Being Investigated on Behalf of Applied Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 12, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Applied Therapeutics, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - APLT
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Applied Therapeutics, Inc. - APLT
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ:APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ATTENTION Applied Therapeutics, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your Rights
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Applied Therapeutics, Inc. (APLT) and Encourages Stockholders to Learn More About the Investigation
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Applied Therapeutics, Inc. (APLT) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Investors to Inquire about Securities Investigation
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. ("Applied Therapeutics" or "the Company") (NASDAQ:APLT). Investors who purchased Applied Therapeutics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/APLT.
Lost Money on Applied Therapeutics, Inc.(APLT)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied Therapeutics, Inc. ("Applied Therapeutics, Inc.") (NASDAQ:APLT) concerning possible violations of federal securities laws. Applied Therapeutics issued a press release on November 27, 2024, announcing "that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for govorestat, a novel, central nervous system (CNS)-penetrant aldose reductase inhibitor (ARI), for the treatment of Classic Galactosemia.
